The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
UK-headquartered clinical-stage company OKYO Pharma’s today shared promising new categorical data analyses from the recent OK-101 Phase II trial in dry eye disease (DED) patients. 10 July 2024
The Sustainable Medicines Partnership (SMP), a collaborative of 48 organizations in the pharmaceutical and healthcare sectors, has published a report into wasted medicines. 10 July 2024
IDEAYA Biosciences (Nasdaq: IDYA) has announced a plan to raise about $263 million in a public share offering, which is expected to close around 11 July. 10 July 2024
Global growth in the pharma market will reach 7.7% through to the end of the decade, according to an analysis from industry commentator Evaluate. 10 July 2024
Lisbon-based Biovance Capital Partners, Portugal’s leading life sciences venture capital (VC) firm, has announced the first closing of its new biotech fund. 10 July 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the National Health Service (NHS) in England. 10 July 2024
The European authorities have granted marketing authorization for Livmarli (maralixibat), for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients from the age of three months. 10 July 2024
USA-based drug conjugates (ADCs) developer Sutro Biopharma
has appointed Barbara Leyman, as chief business development officer, effective July 8, 2024. 10 July 2024
A new report from the USA's Federal Trade Commission (FTC) underlines how the agency regards middlemen as having the potential to inflate drug prices. 10 July 2024
Immunic, a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president. 9 July 2024
During a speech on Tuesday, the UK’s new Secretary of State for Health and Social Care, Wes Streeting, said that he plans to boost the economy through the life sciences sector. 9 July 2024
Shares of Dutch gene therapy company uniQure were up more than 50% at $5.68, after the company released positive early clinical results for its Huntington’s disease candidate. 9 July 2024
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024